FDA approves AI-based vital signs app
The General Authority for Food and Drug Safety has issued a marketing authorization for a digital medical application that relies on artificial intelligence. This app uses the camera of smart devices to measure heart rate, oxygen saturation, and blood pressure through remote photoplethysmography (rPPG) technology. It is the first of its kind to receive a license after a comprehensive evaluation. The app requires calibration of blood pressure measurements with an approved medical device and is not intended for independent diagnosis or emergency cases. This decision aims to support innovation in digital health and promote the safe and organized integration of modern technologies, as part of the Kingdom's efforts to achieve the goals of Vision 2030 and develop the healthcare sector.
Notice: This Is an AI-Generated Summary
Comments (0)